The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Radiation: definitive radiotherapyDrug: induction chemo-immunotherapyDrug: concurrent chemotherapyDrug: Immunotheapy consolidation
- Registration Number
- NCT06139419
- Lead Sponsor
- Sun Yat-sen University
- Brief Summary
This prospective phase II randomized study is to determine the impact of thymosin alpha-1 on the concurrent chemoradiotherpay followed by immunotherapy consolidation in patients with locally advanced NSCLC by assessing the survival outcomes, treatment responses and toxicities.
- Detailed Description
This prospective phase II randomized study is to determine the impact of thymosin alpha-1 on the concurrent chemoradiotherpay followed by immunotherapy consolidation in patients with locally advanced NSCLC by assessing the survival outcomes, treatment responses and toxicities.
Patients with locally advanced NSCLC who will receive concurrent radiochemotherapy followed by immunotherapy consolidation will be randomly divided into two groups (concurrent Tα1 treatment group and control group \[in which Tα1 will not be used\]), and the overall survivals, progression-free survivals (PFS), completion rate of immunotherapy consolidation, toxicities/adverse effects, and peripheral blood immune biomarkers will be compared between these two groups.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 114
- aged ≥18 years old
- histologically confirmed locally advanced and unresectable NSCLC;
- no prior radiotherapy or surgery;
- with the life expectancy over 12 weeks;
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;
- adequate bone marrow and hepatic and renal functions;
- informed consent
- Concurrent enrollment in another clinical trial, unless it is an observational (non-interventional) clinical study;
- With histologically documented combined small-cell lung carcinoma;
- Major surgery (excluding vascular access placement) within 4 weeks prior to enrollment in the study;
- Active or prior documented autoimmune disease within the past 2 years;
- Active or prior documented inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis);
- History of innate immunodeficiency;
- History of organ transplant that requires the use of immunosuppressives;
- A mean heart rate-corrected QT interval (QTc) ≥ 470 ms, calculated using Bazett correction from 3 ECG calculation cycles;
- Poorly managed health conditions that include but are not limited to persistent or active infections, symptomatic congestive heart failure, poorly controlled hypertension, unstable angina, arrhythmia, active peptic ulcer disease or gastritis, active hemorrhagic diseases, hepatitis C or human immunodeficiency virus (HIV) infection, hepatitis B (positive HBsAg and HBV DNA > 500 IU/ml), and mental disorders/social conditions that may hinder the compliance with the study requirements or the ability to give written informed consent willingly;
- Active tuberculosis;
- Receipt of live or attenuated vaccination within 30 days prior to the first dose of the investigational agents;
- History of another primary malignancy within the past 5 years, excluding adequately treated basal or squamous cell skin cancers or cervical carcinoma in situ;
- Pregnant/breastfeeding women or males/females of reproductive potential who do not use contraception.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Control group induction chemo-immunotherapy In control group, participants receive concurrent chemoradiotherapy followed by immunotherapy consolidation. Control group Immunotheapy consolidation In control group, participants receive concurrent chemoradiotherapy followed by immunotherapy consolidation. Concurrent Tα-1 group definitive radiotherapy In this concurrent Tα-1 group, participants receive concurrent chemoradiotherapy followed by immunotherapy consolidation. During this treatment, thymosin alpha-1 was administered at 4.8mg each time. Concurrent Tα-1 group induction chemo-immunotherapy In this concurrent Tα-1 group, participants receive concurrent chemoradiotherapy followed by immunotherapy consolidation. During this treatment, thymosin alpha-1 was administered at 4.8mg each time. Concurrent Tα-1 group concurrent chemotherapy In this concurrent Tα-1 group, participants receive concurrent chemoradiotherapy followed by immunotherapy consolidation. During this treatment, thymosin alpha-1 was administered at 4.8mg each time. Concurrent Tα-1 group Immunotheapy consolidation In this concurrent Tα-1 group, participants receive concurrent chemoradiotherapy followed by immunotherapy consolidation. During this treatment, thymosin alpha-1 was administered at 4.8mg each time. Concurrent Tα-1 group Thymosin Alpha1 In this concurrent Tα-1 group, participants receive concurrent chemoradiotherapy followed by immunotherapy consolidation. During this treatment, thymosin alpha-1 was administered at 4.8mg each time. Control group definitive radiotherapy In control group, participants receive concurrent chemoradiotherapy followed by immunotherapy consolidation. Control group concurrent chemotherapy In control group, participants receive concurrent chemoradiotherapy followed by immunotherapy consolidation.
- Primary Outcome Measures
Name Time Method Completion rate of immunotherapy Calculated from the start of treatment to one year after the last treatment completion Proportion of participants completing 12 months of consolidation of immutherapy
- Secondary Outcome Measures
Name Time Method The absolute count of total lymphocyte in peripheral blood Calculated from the start of treatment to one year after the last treatment completion; up to 18 months Measured at baseline, before immunotherapy, and every 3-4 months thereafter until the end of immunotherapy.
Drop-out rate during the I/O consolidation One year Overall survival 2 years The expression of peripheral blood cytokines (including IL2, IL4, IL6, IL10, TNF-α, and IFN-γ) Calculated from the start of treatment to one year after the last treatment completion; up to 18 months Measured at baseline, before immunotherapy, and every 3-4 months thereafter until the end of immunotherapy.
Incidence of ≥grade 2 pneumonia through study completion, an average of 1 year The absolute count of peripheral blood lymphocyte subsets (including CD3+, CD3+CD4+, CD3+CD8+, CD19+, CD3-CD16+CD56+, and CD56+ NK cells, PD-1+CD8+ T cells, Tim3+ CD8+ T cells, CD62lowCD4+ T cells, PD-1+CD4+ T cells, and Tim3+CD4+ T cells Calculated from the start of treatment to one year after the last treatment completion; up to 18 months Measured at baseline, before immunotherapy, and every 3-4 months thereafter until the end of immunotherapy.
Progression-free survival one year
Trial Locations
- Locations (1)
Sun yat-sen university cancer center
🇨🇳Guangzhou, Guangdong, China